Drug recall · October 16, 2019
Rifampin for Injection recall
Why: Failed Impurities/Degradation Specifications: discoloration due to elevated unknown impurity results which could decrease the effectiveness of the product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Rifampin for Injection, USP, 600 mg/vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL 61103; NDC 67457-445-60.
- Lots / codes
Lot: 7008334, Exp April 2020; 7008417, Exp Oct 2020
- Quantity
- 19,165 vials
- Company
- Mylan Laboratories Limited (Sterile Products Division), Bangalore, N/A
- Distribution
- Nationwide in the USA
- Initiated
- October 7, 2019 · Voluntary: Firm initiated
- Classified
- October 10, 2019
- Reported
- October 16, 2019
- Ended
- March 9, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rifampin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.